CCR2 and obesity disorder: The inhibition of intestinal pro-inflammatory macrophage (M1-type-like) infiltration in genetically engineered animals (Ccr2 knockout mice and tamoxifen-inducible models) or by the oral administration of anti-inflammatory drugs mitigates obesity-associated inflammation and metabolic dysregulation8,10.